Edesa Biotech Q3 loss per share narrows

Reuters08-09
<a href="https://laohu8.com/S/EDSA">Edesa Biotech</a> Q3 loss per share narrows

Overview

  • Edesa Biotech Inc Q3 loss per share narrows to $0.25 from $0.52 last year; net loss remains $1.7 mln

  • Loss from operations stable at $1.9 mln

Result Drivers

  • EB06 FOCUS - Increased expenditures on EB06 for vitiligo study offset by reduced EB05 expenses, supported by government funding

  • EXPENSE MANAGEMENT - Stable operating expenses reflect strategic resource allocation towards EB06 development

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 EPS

-$0.25

Q3 Net Income

-$1.7 mln

Q3 loss from operations

$1.9 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 76.8% above its August 7 closing price of $2.09

Press Release: ID:nGNX4Svytt

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment